Literature review and case study of predominant tubulointerstitial lupus nephritis

以肾小管间质性狼疮性肾炎为主的文献综述及病例研究

阅读:2

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that affects multiple organ systems, and lupus nephritis (LN) primarily involves glomerular, vascular and tubulointerstitial lesions. Renal tubulointerstitial lesions are almost always present alongside glomerular lesions, with isolated renal tubulointerstitial LN being very rare. The aim of this study was to evaluate the clinicopathological features, differential diagnosis, treatment and prognosis of predominant tubulointerstitial lupus nephritis (PTILN). CASE PRESENTATION: We present the case of a 64-year-old Chinese male with severe SLE. The diagnosis of SLE was confirmed on the basis of proteinuria, positive antinuclear antibodies, and immunological and haematological disorders. Renal biopsy revealed severe chronic tubulointerstitial nephritis with excessive immune complex deposition in the tubular basement membrane (TBM), mild glomerular lesions and minimal immune complex deposition, suggesting predominant tubulointerstitial LN. The patient was treated with steroids and mycophenolate mofetil, leading to stabilization of renal function. In the literature review, we identified a total of 18 patients whose predominant tubulointerstitial LN was reported. In our analysis, we evaluated the clinical and pathological features, treatment, and prognosis of this condition in these patients. CONCLUSIONS: This case series reinforces PTILN as a distinct LN variant characterized by dominant tubulointerstitial inflammation and TBM immune deposits. Although PTILN shares clinical features with classic LN, PTILN exhibits notable heterogeneity in demographics, pathology, and outcomes, and its pathogenesis, diagnostic criteria, and optimal management require further elucidation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。